Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SPRB 
Spruce Biosciences Inc (SPRB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: SPRB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -76.86% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.08M USD | Price to earnings Ratio - | 1Y Target Price 1.83 |
Price to earnings Ratio - | 1Y Target Price 1.83 | ||
Volume (30-day avg) 267612 | Beta 2.34 | 52 Weeks Range 0.26 - 0.87 | Updated Date 04/1/2025 |
52 Weeks Range 0.26 - 0.87 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.95 |
Earnings Date
Report Date 2025-03-11 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1562.79% |
Management Effectiveness
Return on Assets (TTM) -30.35% | Return on Equity (TTM) -57.55% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -44607692 | Price to Sales(TTM) 1.56 |
Enterprise Value -44607692 | Price to Sales(TTM) 1.56 | ||
Enterprise Value to Revenue 15.32 | Enterprise Value to EBITDA -0.23 | Shares Outstanding 41302600 | Shares Floating 24071981 |
Shares Outstanding 41302600 | Shares Floating 24071981 | ||
Percent Insiders 11.57 | Percent Institutions 44.05 |
Analyst Ratings
Rating 3 | Target Price 1.83 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 5 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Spruce Biosciences Inc
Company Overview
History and Background
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need. Founded in 2014, the company has primarily focused on developing tildacerfont, a novel, potent, and selective oral 11u03b2-HSD1 inhibitor.
Core Business Areas
- Pharmaceutical Development: Development and commercialization of therapeutics for rare endocrine disorders, specifically congenital adrenal hyperplasia (CAH).
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of tildacerfont.
Leadership and Structure
The company's leadership team includes Javier Szwarcberg, M.D., M.P.H. (Chief Executive Officer). The organizational structure is typical of a clinical-stage biotech company, focused on research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- Tildacerfont: Tildacerfont is Spruce Biosciences' lead product candidate, an oral non-steroidal therapy being developed for classic congenital adrenal hyperplasia (CAH). The company is primarily focusing on adult CAH. Market share data is not yet available as the drug is still in development. Potential competitors include Crinetics Pharmaceuticals (CRNX) and Neurocrine Biosciences (NBIX).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with a focus on developing novel therapies for unmet medical needs. The rare disease space is attractive due to regulatory incentives and potential for orphan drug designation.
Positioning
Spruce Biosciences is positioned as a company specializing in rare endocrine disorders, specifically CAH, with tildacerfont as its lead asset. The company aims to address the unmet needs of CAH patients with a non-steroidal therapy.
Total Addressable Market (TAM)
The estimated TAM for CAH treatment is significant, with current treatments often involving long-term steroid use and associated side effects. Spruce aims to capture a portion of this market with tildacerfont. The exact TAM figures vary depending on the source and prevalence estimates, but are estimated to be in the hundreds of millions of dollars. Spruce is positioned to be a significant player pending regulatory approval.
Upturn SWOT Analysis
Strengths
- Focus on a specific rare disease with high unmet need
- Novel non-steroidal therapy
- Experienced management team
- Orphan Drug Designation potential
Weaknesses
- Single product pipeline
- Clinical trial risks
- Dependence on regulatory approval
- Limited commercial infrastructure
Opportunities
- Expansion into other indications for tildacerfont
- Potential partnerships or acquisitions
- Favorable regulatory environment for rare diseases
- Growing awareness of CAH and need for better treatments
Threats
- Clinical trial failures
- Competition from other companies developing CAH treatments
- Regulatory setbacks
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- CRNX
- NBIX
Competitive Landscape
Spruce Biosciences competes with other companies developing treatments for CAH. The competitive landscape is evolving, with both established pharmaceutical companies and smaller biotech firms pursuing novel therapies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by R&D progress and clinical trial advancements.
Future Projections: Future growth is dependent on the successful development and commercialization of tildacerfont. Analyst projections are based on the potential market opportunity and the likelihood of regulatory approval.
Recent Initiatives: Recent initiatives include advancing tildacerfont through clinical trials and preparing for potential commercialization.
Summary
Spruce Biosciences is a clinical-stage biotech company focused on rare endocrine disorders. The company's future hinges on the successful development and commercialization of tildacerfont. Clinical trial results and regulatory approvals are key milestones to watch. They need to successfully navigate clinical trials and regulatory hurdles.
Similar Companies
ALNY
Alnylam Pharmaceuticals Inc
ALNY
Alnylam Pharmaceuticals Inc
CRNX
Crinetics Pharmaceuticals Inc
CRNX
Crinetics Pharmaceuticals Inc
NBIX
Neurocrine Biosciences Inc
NBIX
Neurocrine Biosciences Inc
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Spruce Biosciences Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2020-10-09 | CEO & Director Dr. Javier Szwarcberg M.D., M.P.H. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 22 | Website https://sprucebio.com |
Full time employees 22 | Website https://sprucebio.com | ||
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.